English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [1945]
News [3579]
Articles [92]
Editorials [5]
Conferences [156]
elearning [19]
Challenges of managing patients with NMIBC: from risk stratification to...
Dr Benjamin Pradère, Dr Bernadett Szabados, Prof Shahrokh Shariat
Challenges of managing patients with NMIBC: from risk stratification to treatment and beyond ( Dr Benjamin Pradère, Dr Bernadett Szabados, Prof Shahrokh Shariat )
22 Mar 2025
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant...
Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )
11 Mar 2025
CaboNivo shows sustained long-term benefits for survival and tumour progression...
Prof Camillo Porta - University of Bari, Bari, Italy,
CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC ( Prof Camillo Porta -  University of Bari, Bari, Italy, )
20 Feb 2025
ASCO GU 2025: Latest updates in mRCC
Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...
ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )
19 Feb 2025
Prophylactic tocilizumab prior to infusion of anti-CD19 CAR-T ce may reduce...
Dr Wiebke Rösler - University Hospital Zurich, Zurich, Switzerland
Prophylactic tocilizumab prior to infusion of anti-CD19 CAR-T ce may reduce toxicity in older lymphoma patients ( Dr Wiebke Rösler - University Hospital Zurich, Zurich, Switzerland )
13 Feb 2025
Optimising immunoglobulin dosing can enhance patient outcomes in multiple...
Dr Elizabeth O'Donnell - Dana-Farber Cancer Institute, Boston, USA
Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma ( Dr Elizabeth O'Donnell - Dana-Farber Cancer Institute, Boston, USA )
14 Jan 2025
High-fibre dietary intervention in precursor plasma cell disorders improves...
Dr Urvi Shah - Memorial Sloan Kettering Cancer Center, New York, USA
High-fibre dietary intervention in precursor plasma cell disorders improves biomarkers of disease, may delay progression to myeloma ( Dr Urvi Shah - Memorial Sloan Kettering Cancer Center, New York, USA )
9 Jan 2025
Lack of benefit of auto-HCT in MCL patients in first complete remission with...
Dr Robert Dean - Cleveland Clinic Taussig Cancer Center, Cleveland, USA
Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD ( Dr Robert Dean - Cleveland Clinic Taussig Cancer Center, Cleveland, USA )
9 Jan 2025
KRdc as induction therapy shows improved OS for NDMM patients
Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
KRdc as induction therapy shows improved OS for NDMM patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )
20 Dec 2024
Targeted therapies associated with increased risk for and incidence of...
Dr James Martin - Cleveland Clinic, Cleveland, USA
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )
20 Dec 2024
Teclistamab-lenalidomide and teclistamab alone can be safely administered as...
Dr Elena Zamagni - University of Bologna, Bologna, Italy
Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )
18 Dec 2024
Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus...
Dr Adam Olszewski - Brown University, Providence, USA
Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL ( Dr Adam Olszewski - Brown University, Providence, USA )
18 Dec 2024
<12345...163>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top